These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 10915790)
1. alpha-Synuclein membrane interactions and lipid specificity. Jo E; McLaurin J; Yip CM; St George-Hyslop P; Fraser PE J Biol Chem; 2000 Nov; 275(44):34328-34. PubMed ID: 10915790 [TBL] [Abstract][Full Text] [Related]
2. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148 [TBL] [Abstract][Full Text] [Related]
3. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Conway KA; Harper JD; Lansbury PT Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204 [TBL] [Abstract][Full Text] [Related]
4. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Li J; Uversky VN; Fink AL Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511 [TBL] [Abstract][Full Text] [Related]
6. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. Zhu M; Li J; Fink AL J Biol Chem; 2003 Oct; 278(41):40186-97. PubMed ID: 12885775 [TBL] [Abstract][Full Text] [Related]
7. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Bussell R; Eliezer D Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050 [TBL] [Abstract][Full Text] [Related]
8. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Madine J; Doig AJ; Middleton DA Biochemistry; 2006 May; 45(18):5783-92. PubMed ID: 16669622 [TBL] [Abstract][Full Text] [Related]
9. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935 [TBL] [Abstract][Full Text] [Related]
10. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856 [TBL] [Abstract][Full Text] [Related]
11. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854 [TBL] [Abstract][Full Text] [Related]
12. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Kahle PJ; Neumann M; Ozmen L; Haass C Ann N Y Acad Sci; 2000; 920():33-41. PubMed ID: 11193173 [TBL] [Abstract][Full Text] [Related]
13. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Hoyer W; Cherny D; Subramaniam V; Jovin TM Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017 [TBL] [Abstract][Full Text] [Related]
14. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein. O'Leary EI; Jiang Z; Strub MP; Lee JC J Biol Chem; 2018 Jul; 293(28):11195-11205. PubMed ID: 29853639 [TBL] [Abstract][Full Text] [Related]
15. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. El-Agnaf OM; Jakes R; Curran MD; Wallace A FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427 [TBL] [Abstract][Full Text] [Related]
16. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Conway KA; Harper JD; Lansbury PT Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558 [TBL] [Abstract][Full Text] [Related]
17. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. Ramakrishnan M; Jensen PH; Marsh D Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533 [TBL] [Abstract][Full Text] [Related]
18. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Conway KA; Lee SJ; Rochet JC; Ding TT; Williamson RE; Lansbury PT Proc Natl Acad Sci U S A; 2000 Jan; 97(2):571-6. PubMed ID: 10639120 [TBL] [Abstract][Full Text] [Related]
19. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782 [TBL] [Abstract][Full Text] [Related]
20. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Wersinger C; Prou D; Vernier P; Niznik HB; Sidhu A Mol Cell Neurosci; 2003 Sep; 24(1):91-105. PubMed ID: 14550771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]